文献速递关节外科

全髋关节置换术前抗病毒治疗丙型肝炎能否降低并发症风险?一项匹配队列研究

Does Preoperative Antiviral Treatment for Hepatitis C Decrease Risk of Complications After Total Hip Arthroplasty? A Matched Cohort Study.
PubMed 文献 · J Arthroplasty · 2022-03-03

该回顾性匹配队列研究利用行政索赔数据库,将6,883例HCV患者与20,694例非感染对照按1:3匹配,并将920例术前接受抗病毒治疗的HCV患者与3,820例未治疗HCV患者按1:4匹配,比较90天内科并发症和术后2年关节并发症。结果显示HCV患者并发症风险显著升高,而术前抗病毒治疗可降低再入院和假体周围感染风险。

要点

  • HCV患者全髋置换术后90天内内科并发症及2年内翻修、脱位、机械并发症、假体周围骨折和假体周围感染风险均显著高于非感染对照。
  • 术前接受抗病毒治疗的HCV患者2年内所有关节并发症风险与对照无显著差异。
  • 与未治疗HCV患者相比,治疗者90天内再入院风险(OR 0.58)和2年假体周围感染风险(OR 0.62)显著降低。

核心结论

  • HCV患者全髋关节置换术后内科和关节并发症风险显著高于对照,但术前抗病毒治疗可减轻并发症风险。
  • 治疗HCV患者较未治疗HCV患者90天内再入院和2年假体周围感染风险显著降低。

研究设计与样本

  • 回顾性匹配队列研究,使用行政索赔数据库。
  • 6,883例HCV患者与20,694例非感染对照按1:3匹配;920例术前抗病毒治疗的HCV患者与3,820例未治疗HCV患者按1:4匹配。
  • 采用多变量逻辑回归比较90天内科并发症和术后2年关节并发症发生率。

主要发现

  • HCV患者90天内内科并发症发生率显著高于非感染对照(所有P < .01)。
  • 术后2年HCV患者翻修THA风险OR 1.81、脱位OR 2.06、机械并发症OR 1.40、假体周围骨折OR 1.76、假体周围感染OR 1.79,均显著高于对照。
  • 治疗HCV患者2年内所有关节并发症风险与对照相比无统计学显著差异(所有P > .05)。
  • 治疗HCV患者较未治疗HCV患者90天内再入院风险OR 0.58、2年假体周围感染风险OR 0.62,均显著降低。

局限性

  • 证据等级为Level III。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatitis C virus (HCV) is associated with increased complication risk after elective arthroplasty. The purpose of this study is to examine the impact of HCV and prearthroplasty antiviral treatment on complications following total hip arthroplasty (THA). METHODS: A retrospective matched cohort study was conducted using an administrative claims database. In total, 6,883 HCV patients were matched 1:3 with 20,694 noninfected controls, and 920 HCV patients with antiviral treatment before THA (treated HCV) were matched 1:4 with 3,820 HCV patients without treatment (untreated HCV). Rates of 90-day medical complications and joint complications within 2 years postoperatively were compared with multivariable logistic regression. RESULTS: HCV patients exhibited significantly increased rates of medical complications within 90 days compared to noninfected controls (all P < .01). At 2 years postoperatively, HCV patients also exhibited significantly higher risk of revision THA (odds ratio [OR] 1.81), dislocation (OR 2.06), mechanical complications (OR 1.40), periprosthetic fracture (OR 1.76), and prosthetic joint infection (PJI) (OR 1.79). However, treated HCV patients exhibited statistically comparable risk of all joint complications at 2 years postoperatively relative to controls (all P > .05). Compared to untreated HCV patients, treated HCV patients exhibited significantly lower risk of inpatient readmission within 90 days (OR 0.58) and PJI at 2 years postoperatively (OR 0.62). CONCLUSION: HCV patients exhibit significantly increased risk of medical and joint complications following THA relative to controls, though prearthroplasty antiviral treatment mitigates complication risk. Treated HCV patients exhibited significantly lower risk of inpatient readmission and PJI compared to untreated HCV patients. LEVEL OF EVIDENCE: Level III.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Ross AJ, Ross BJ, Lee OC, et al. Does Preoperative Antiviral Treatment for Hepatitis C Decrease Risk of Complications After Total Hip Arthroplasty? A Matched Cohort Study. J Arthroplasty. 2022. PMID: 35248753. doi:10.1016/j.arth.2022.02.102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。